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Background: Urea cycle disorders (UCDs) are inborn errors of 
ammonia detoxification. Ammonia is detoxified by its conversion 
to urea in the liver.
Aim: To evaluate the spectrum of UCDs and the outcome of 
patients with UCDs in India
Materials and Methods: This was a retrospective study of 
patients with UCDs who presented to our center during 2000 
to 2016. We biochemically suspected a UCD in 59 patients (34 
males and 25 females) who had typical clinical symptoms. Pres-
ence of UCD was confirmed in 36 (24 males and 12 females) 
patients by molecular studies.
Results: Molecular diagnosis showed presence of citrullinemia 
type I in 23 patients, argininosuccinic aciduria in 6, ornithine 
transcarbamylase deficiency (OTCD) in 3, carbamoyl phosphate 
synthetase 1 deficiency in 1, N-acetyl glutamate synthase defi-
ciency in 2, and arginase deficiency (ARGD) in 1.
Of the 36 patients with confirmed UCD, 23 died (63.9% 
mortality), 3 were lost to follow-up, and 10 (5 with argininosuc-
cinate synthetase deficiency, 1 with argininosuccinate lyase defi-
ciency, 3 with OTCD, and 1 with ARGD) are being followed up 
regularly and have good metabolic control.
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Conclusion: In India, owing to the absence of newborn 
screening, UCDs are detected only after development of symp-
toms, resulting in a high rate of morbidity and mortality (23 
of 36 patients died). Citrullinemia type I is the commonest 
UCD (detected in 23 of 36 patients), with the common muta-
tion p.Gly390Arg seen in more than half of the patients with the 
disorder (52.17%). Early and aggressive treatment has resulted in 
good outcome in only 2 patients, while 4 were mildly affected. Of 
those alive, 50% have epilepsy, 40% have cerebral palsy, and 40% 
have neurobehavioral problems.
Key Words: Urea cycle disorder, hyperammonemia, citrul-
linemia, argininemia, ornithine transcarbamylase deficiency, 
argininosuccinic aciduria, carbamoyl phosphate synthetase 1 
deficiency, N-acetyl glutamate synthase deficiency, hyperornith-
inemia–hyperammonemia–homocitrullinuria syndrome
Introduction
Urea cycle disorders (UCDs) are inborn errors of 
ammonia detoxification. Ammonia that is produced 
from amino acid metabolism is detoxified mainly 
through its conversion to urea in the liver (Figure). 
The enzymes involved in UCDs are carbamoyl phos-
phate synthetase 1 (CPS1), N-acetyl glutamate synthase 
(NAGS), ornithine transcarbamylase (OTC), arginino-
succinate synthetase (ASS), argininosuccinate lyase, and 
arginase. Often, infants with a UCD initially appear 
normal but can rapidly develop cerebral edema and 
the related signs including lethargy, vomiting, feeding 
difficulties, hyperventilation or hypoventilation, hypo-
thermia, seizures, neurologic posturing, and coma.1 The 
incidence of these disorders in the United States has 
been estimated to range from 1:14,000 for ornithine 
transcarbamylase deficiency (OTCD) to 1:3,50,000 
for arginase deficiency (ARGD).2 A recent study found 
an overall incidence of 1:35,000.3 However, in India, 
since formal nationwide newborn screening (NBS) is 
not available, data regarding the incidence of UCD are 
not available. In our practice, we have come across 36 of 
833 (4.32%) critically ill newborns with a biochemical 
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profile suggesting a UCD.4 Though this does not indi-
cate the incidence of UCD in the Indian population, it 
provides an idea about the incidence of UCDs among 
critically ill newborns.
Figure. The Urea Cycle
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Materials and Methods
This was a retrospective study of patients with 
UCDs who presented to the Navi Mumbai Insti-
tute of Research in Mental and Neurological Hand-
icap (NIRMAN; Navi Mumbai, Maharashtra, India) 
from 2000 to 2016. Based on the biochemical profile, 
we suspected the presence of a UCD in 59 patients 
(34 males and 25 females) presenting with hyperam-
monemia, vomiting, convulsions, failure to thrive, 
and lethargy. Among the entire cohort, 36 patients 
were confirmed to have a UCD by molecular studies. 
Of these, 24 were males and 12 were females (Table 
1). Clinically and biochemically, N-acetyl glutamate 
synthase deficiency (NAGSD) or carbamoyl phos-
phate synthetase 1 deficiency (CPS1D) was suspected 
in 9 patients, but it could not be confirmed by muta-
tion analysis. Hyperornithinemia–hyperammonemia–
homocitrullinuria syndrome was suspected in 2 patients 
and lysinuric protein intolerance was suspected in 1 
patient. However, these also could not be confirmed 
by gene sequencing. One family with 2 neonatal deaths 
with early-onset hyperammonemic encephalopathy 
was also included in our cohort. No gene studies were 
performed in the index cases. The parents were screened 
and found to be carriers for NAGS mutations.
Biochemical analysis was performed for each patient 
at our center. Ammonia was analyzed by dry chem-
istry (VITROS Chemistry System, Johnson & 
Johnson Clinical Diagnostics, NJ, USA/Fujifilm Dri 
Chem NX500i, Tokyo, Japan). Urinary orotic acid 
was quantified using high-performance liquid chro-
matography (Waters Corporation, MA, USA); amino 
acids in plasma and urine were quantified using ultra–
high-performance liquid chromatography (UHPLC) 
(Agilent Technologies, 1200 Infinity Series, CA, USA). 
Argininosuccinic acid quantitation was also done 
using UHPLC (Agilent Technologies) in patients with 
elevated levels of citrulline to rule out argininosuccinic 
aciduria (ASA). Follow-up was performed using the 
same analytical techniques and, in some cases, tandem 
mass spectrometry using dried blood spots.
Molecular studies were performed in each patient for 
confirmation of the presence of UCD. Gene sequencing 
was done at Zurich University (Zurich, Switzerland) 
by standard methods. In brief, for analysis of the ASS1, 
ASL, OTC, or ARG genes, DNA from peripheral 
blood cells was used for exon-wise polymerase chain 
reaction amplification followed by sequencing. For CPS1 
analysis, RNA was isolated from lymphocytes after 
a short-time culture in the presence of phytohemag-
glutinin followed by reverse transcription polymerase 
chain reaction and sequencing of fragments of the 
CPS1 transcript.5 Identified mutations were confirmed 
in parental DNA whenever this was available. Multi-
plex ligation-dependent probe amplification or dele-
tion/duplication studies were not done in this cohort. 
Mutation testing was done after informed consent was 
obtained from the parents or legal guardians.
Results
Of the 59 patients who were clinically and biochemi-
cally suspected to have a UCD, presence of a UCD 
was confirmed in 36 by molecular studies. Molecular 
diagnosis confirmed citrullinemia type I in 23 patients, 
ASA in 6, OTCD in 3, CPS1D in 1, NAGSD in 2, and 
argininemia in 1. No mutations could be identified in 
23 of 59 patients. Of these, 7 patients were suspected to 
have OTCD. Findings on gene sequencing for OTCD 
in these patients were normal; however, deletion/dupli-
cation studies were not performed.
In our cohort of 36 patients with confirmed UCD, 23 
died, 3 were lost to follow-up, and 10 are being followed 
up in our clinic with regular clinical and biochemical 
monitoring. Patient details are provided in Table 1.
Of the 23 patients with argininosuccinate synthase defi-
ciency (ASSD), 15 died, 3 were lost to follow-up, and 5 
are alive. Of the 6 patients with argininosuccinate lyase 
deficiency (ASLD), 5 died and only 1 is alive and under 
irregular follow-up. All 3 patients with OTCD are alive 
and are under regular follow-up. Both the patients with 
NAGSD died. The patient with ARGD is alive and 
the patient with CPS1D died. Overall, 10 patients are 
being followed up regularly.
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Table 1. Distribution of the Cohort According to Sex 















ASSD 23 13 10 5 15 3
ASLD 6 5 1 1 5 0
OTCD 3 2 1 3 0 0
NAGSD 2 2 0 0 2 0
ARGD 1 1 0 1 0 0
CPS1D 1 1 0 0 1 0
Total 36 24 12 10 23 3
ARGD, arginase deficiency; ASLD, argininosuccinate lyase deficiency; 
ASSD, argininosuccinate synthase deficiency; CPS1D, carbamoyl 
phosphate synthetase 1 deficiency; NAGSD, N-acetyl glutamate 
synthase deficiency; OTCD, ornithine transcarbamylase deficiency.
In our cohort, all the patients with citrullinemia 
presented in the early newborn period. Age at presen-
tation ranged from 1 day to 4 months, with a mean of 
14 days (Table 2). Five patients with ASLD presented 
in the newborn period (< 7 d) and 1 patient presented 
at 2 years of age. All 3 patients with OTCD and 1 with 
ARGD presented around 2 years of age. The patient 
with CPS1D presented at the age of 1 month. 
Of the 36 patients, 31 presented in the neonatal period 
before 4 weeks of life (86.11%) and only 5 presented 
after 4 weeks of life. The mortality rate in the neonatal 
presenters was 71% (22 of 31) and it was 20% in those 
who had late-onset presentation (1 of 5) (Table 3).
In patients 35 and 36, no investigations were 
performed. Both were siblings and died of hyperam-
monemia in the neonatal period. Parents were screened 
molecularly and were found to be carriers of mutation 
p.Gln331* in exon 4 of the NAGS gene.
Neurologic outcomes of patients
Table 4 shows the degree of neurologic outcomes.
Normal neurologic outcome (2 of 10)
Normal mental and physical development was seen 
in 1 male patient with OTCD (patient # 31). This 
child is treated with sodium benzoate at a dose of 250 
mg/kg/d, arginine at a dosage of 250 mg/kg/d, and 
protein restriction. Because of the financial constraints, 
parents cannot afford special formulas.
One child with ASSD (male, patient # 12) who received 
a transplant at the age of 6 months also has normal 
milestones without any seizure disorders. Although 
this child has persistently elevated levels of citrulline 
on follow-up (mean citrulline level = 1,800 µmol/L), he 
does not have episodes of hyperammonemia.
Mild neurologic disorder (4 of 10)
Four patients (2 with ASSD: 1 male, patient # 5 and 
1 female, patient # 22 and 2 with OTCD: 1 male, 
patient # 30 and 1 female, patient # 32) have milder 
neurologic outcome. Two patients with citrullinemia 
type I (1 male, patient # 5 and 1 female, patient # 22) 
have normal physical development. They have achieved 
normal motor and mental milestones but have hyper-
activity disorder, learning disabilities, and behav-
ioral problems. The male child also had episodes of 
seizures, which was successfully treated with leveti-
racetam, and findings on electroencephalogram (EEG) 
were abnormal. The female child required medication 
for hyperactivity disorder for 2 years. No seizures or 
abnormal findings on EEG were detected. A formal 
psychologic evaluation was not performed.















ASSD 23 15 0 0
ASLD 5 4 1 1
OTCD 0 0 3 0
NAGSD 2 2 0 0
ARGD 0 0 1 0
CPS1D 1 1 0 0
Total 31 22 (71%) 5 1 (20%)
ARGD, arginase deficiency; ASLD, argininosuccinate lyase deficiency; 
ASSD, argininosuccinate synthase deficiency; CPS1D, carbamoyl 
phosphate synthetase 1 deficiency; NAGSD, N-acetyl glutamate 
synthase deficiency; OTCD, ornithine transcarbamylase deficiency.
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Table 2. Patient Information Including the Mutations and Outcome
Patient Number Age at Onset Sex Exon Nucleotide Change Protein Change Outcome
ASSD
1 3 d Male 15 c.1168G>A p.Gln390Arg Died
2 5 d Male 15 c.1168G>A p.Gln390Arg Died
3 3 d Female 7 c.470G>A p.Arg157His
Alive (epilepsy, 
severe mental 
retardation, and bed 
ridden) 
4 2 d Male 15 c.1168G>A p.Gln390Arg Died
5 1 d Male 15 c.1168G>A p.Gln390Arg








6 2 d Female 15 c.1168G>A p.Gln390Arg Died
7 6 d Female 15 c.1139delA p.Gln380Argfs*19 Died
8 6 d Female 15 c.1168G>A p.Gln390Arg Died
9 7 d Male 15 c.1168G>A p.Gln390Arg Died
10 4 d Male 15 c.1168G>A p.Gln390Arg Died
11 6 d Female 13 c.190C>T p.Arg304Trp Died
12 16 d Male 15 c.1168G>A p.Gln390Arg
Alive (normal 
physical and mental 
development, on 
normal diet, liver Tx 
at the age of 6 mo)
13 2 d Female 12 c.815G>A p.Arg272His Lost to follow-up 





Lost to follow-up 
15 5 d Male 5 c.269G>A p.Gly90Asp Died
16 4 mo Male 15 c.1168G>A p.Gln390Arg Died
17 2 d Male 7 c.470G.A p.Arg157His
Alive (severe 
developmental 
delay and mental 
retardation; H/o 
seizure disorder)
18 6 d Male 15 c.1168G>A p.Gln390Arg Died
19 8 d Female 15 c.1168G>A p.Gln390Arg Died
20 7 d Female 12 c.793C>T p.Arg265Cys Lost to follow-up 
21 5 d Male 13 c.910C>T p.Arg304Trp Died




normal with learning 
disabilities and 
hyperactivity) 
23 2 d Male 7 c.470G>A p.Arg157His Died
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ASLD
24 2 y Male 15 c.1153C>T p.Arg385Cys
Died (the child was 
developing normally 
with slight learning 
difficulty, was 
attending regular 
school; he died at 
the age of 11 y due 
to severe dengue 
infection)
25 2 d Male 4 c.337C>T p.Arg113Trp Died
26 2 y Female 4 c.337C>T p.Arg113Trp
Alive (delayed 
physical and mental 
milestones with 
hepatomegaly and 
abnormal LFT; H/o 
seizure disorders 
and poor follow-up; 
suggested liver Tx)
27 2 d Male 11 c.857A>G p.Gln286Arg Died
28 5 d Male 12 c.967A>G p.Lys323Glu Died
29 4 d Male 8 c.649C>T p.Arg217* Died
OTCD










31 3 y Male 4 c.386G>A p.Arg129His
Alive (normal 
physical and mental 
milestones and no 
ADHD or behavioral 
abnormalities)
32 2 y Female 7 c.674C>T p.Pro225Leu
Alive (episodic 
hyperammonemia, 




33 12 y Male 1 c.2T>C p.Met1Thr






34 1 mo Male 19 c.2339G>A p.Arg780His Died
NAGSD
35 7 d Male — — — Died
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36 2 d Male — — — Died
Two children with OTCD (1 male, patient # 30 and 
1 female, patient # 32) have normal physical develop-
ment. The male child, who is now 11 years old, has 
achieved milestones but has attention-deficit/hyper-
activity disorder and stubborn behavior. He has had 
2 to 3 episodes of hyperammonemia requiring peri-
toneal dialysis. However, since 1 year, after the initia-
tion of treatment with sodium benzoate at a dosage 
of 250 mg/kg/d and arginine at a dosage of 250 mg/
kg/d and a special diet, he is keeping well. The female 
child has been recently diagnosed with OTCD and 
has mildly delayed mental milestones; treatment with 
sodium benzoate at a dosage of 250 mg/kg/d, arginine 
at a dosage of 150 mg/kg/d, and citrulline at a dosage 
of 150 mg/kg/d has been initiated. She recently had 
seizure episodes of hyperammonemia associated with 
enteric fever. 
Severe neurologic disorder (4 of 10)
Four patients have severe neurologic sequelae. Of 
these, 2 have ASSD (1 male, patient # 17 and 1 female, 
patient # 3), 1 has ASLD (female, patient # 26), and 1 
has ARGD (male, patient # 33). Both the patients with 
ASSD have severe developmental delay with seizure 
disorder.
The child with ASLD has delayed motor and mental 
milestones with hepatomegaly and abnormal findings 
on liver function tests (LFTs). She has episodic hyper-
ammonemia and has been advised liver transplantation.
The child with ARGD has grossly delayed milestones, 
is nonambulatory, with spastic paraplegia and multiple 
seizure episodes. 
Discussion
Summar et al3 and Batshaw et al6 have identified 
OTCD as the most common UCD worldwide. Citrul-
linemia type I was the most common UCD seen in our 
cohort (20 patients, 34%). This is also supported by 
another study by Bijarnia et al,7 which was conducted 
at a metabolic center in India. Hence, in the Indian 
population, citrullinemia type I seems to be the 
most common UCD. It is also the commonest UCD 
in Turkey, with a prevalence of 13 of 21 total UCDs 
(62%).8 Furthermore, in our cohort, 12 patients with 
citrullinemia type I (52.2%) (24 alleles) had a common 
mutation (exon 15: c.1168G>A/p.Gln390Arg). This 
mutation has been reported globally as the most prev-
alent mutation9 and, more specifically, was also the 
single commonest mutation in other populations.10 The 
mutation p.Gln390Arg is located in the oligomeriza-
tion domain of ASS and probably hampers tetramer 
formation. As ASS functions as a tetramer, a defect 
in this domain can be expected to be severe, which is 
supported by the findings in this patient series.
The overall mortality rate was 63.8% in our cohort. We 
found the mortality rate to be 65.2% in patients with 
citrullinemia and 83.3% in those with ASA. The most 
common precipitant was found to be intercurrent infec-
tions. Due to the absence of NBS, most of the cases 
presented to us in a state of severe metabolic decompen-
sation. Moreover, injectable sodium phenylacetate and 
sodium benzoate are not available in India. Only oral 
Jalan A, et al. Survival and Outcome of Patients With UCD
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Table 4. Degree of Neurologic Deficit in 10 Cases
Degree of 
Neurologic Deficit














ARGD, arginase deficiency; ASLD, argininosuccinate lyase deficiency; 
ASSD, argininosuccinate synthase deficiency; OTCD, ornithine 
transcarbamylase deficiency.
ADHD, attention-deficit/hyperactivity disorder; ARGD, arginase deficiency; ASLD, argininosuccinate lyase deficiency; ASSD, argininosuccinate synthase 
deficiency; CPS1D, carbamoyl phosphate synthetase 1 deficiency; H/o, history of; NAGSD, N-acetyl glutamate synthase deficiency; OTCD, ornithine 
transcarbamylase deficiency; Tx, transplant.
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sodium benzoate is available at select centers, making 
the administration of emergency protocols difficult.11 
Hence, a high rate of mortality was seen in our cohort 
compared with the worldwide mortality rates (24%).6 
One study has found 92% 1-year survival rate in a series 
of 26 children with inborn errors of urea synthesis and 
79% of the survivors had one or more developmental 
disabilities.12 Another study has reported a mortality 
rate of 84% for all defects combined in the neonatal 
presenters,11,13 whereas in our cohort, it was 69%.
In a retrospective study conducted in Europe, a poor 
cognitive outcome was observed in patients whose 
plasma ammonia concentration exceeded 300 µmol/L 
initially or was 480 µmol/L at its peak.14 Most of the 
critically ill children in our study had peak ammonia 
concentration > 480 µmol/L and they either died 
or have abnormal neurologic outcome. Many major 
centers in India do not have in-house testing facilities 
for plasma ammonia, and samples are sent across cities, 
wasting time and reducing the reliability of analysis. 
Moreover, regular ammonia monitoring and keeping 
a record of it is scarcely available in such critical cases, 
thereby making predictions about outcome practically 
impossible. In our observation, newborns presenting 
with hyperammonemia have ammonia levels generally 
above 400 µmol/L.
Another important factor for a good neurologic 
outcome, besides early diagnosis, is regular follow-up 
and appropriate treatment. In India, sodium benzoate, 
only for oral treatment, which is usually food grade 
(not pharmaceutical grade), and L-arginine are avail-
able. Sodium phenylbutyrate is not easily available in 
India.11 Special amino acid supplements containing all 
essential amino acids except for arginine, citrulline, and 
ornithine (UCD diets) are now being manufactured 
locally, but compliance due to taste and cost is a major 
issue. Good-quality special amino acid supplements 
from international brands are expensive and not easily 
available.
A female child recently diagnosed with OTCD under-
went magnetic resonance imaging (MRI) during her 
admission for hyperammonemia, which revealed gyral 
swelling involving insular cortices; cingulated gyri; and 
grey matter of frontal, temporal, and parietal lobes, 
along with gliotic changes in both the frontal lobes. A 
follow-up scan for this child has been planned.
The Urea Cycle Disorders Consortium15 has provided 
guidelines and suggested MRI with magnetic resonance 
spectroscopy for regular follow-up of patients with 
UCD for improving neurologic outcome. However, this 
modality is barely acceptable by Indian patients because 
it is expensive. Since genetic disorders including meta-
bolic diseases are not covered under any insurance in 
India, even the few patients who have such insurance 
are not eligible for financial support.
All the patients with UCD are subjected to a standard 
treatment protocol of oral sodium benzoate at a dosage 
range of 100 to 250 mg/kg/d, L-arginine at a dosage 
of 250 mg/g/d (except for patients with ARGD), and 
supplementation of L-citrulline at a dosage of 170 mg/
kg/d (for patients with OTCD). Diet is monitored, and 
low-protein diet along with supplementation of special 
UCD formula is recommended. Despite attempts 
to treat patients diagnosed with UCDs, 70% of the 
patients died. None of these patients were detected by 
NBS. Five children with citrullinemia type I, 1 with 
ASA, 3 with OTCD, and 1 with argininemia are being 
followed up regularly (n = 10) and are under good 
metabolic control.
One child with citrullinemia type I received an ortho-
topic liver transplant (OLT) at the age of 6 months and 
is developing normally both physically and mentally 
and is on a normal diet, without any episodes of hyper-
ammonemia; however, the orotic acid and citrulline 
levels in this patient remained consistently high (average 
citrulline level was > 2000 µmol/L). Whitington et al16 
have documented good recovery in 14 of 16 patients. 
OLT is an alternative to medical therapy for severe 
UCDs and OLT results show complete metabolic 
correction and cessation but not reversal of neurologic 
deficits.16 Outcome after OLT is generally very good, 
and in 2004, there was already an admirable recovery, 
and 100% survival in 5 children with UCD (2 male 
children with OTCD, 2 male children with CPS1D, 
and 1 female child with OTCD who was resistant to 
medical therapy) was reported.17
Follow-up Report
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Two patients with citrullinemia have reached early 
adolescence and have shown good metabolic control 
with dietary compliance. These patients are physically 
normal but mildly affected neurologically, with behav-
ioral problems, hyperactivity disorder, and learning 
disabilities. Two male children with OTCD are devel-
oping well physically but have hyperactivity and 
learning disabilities. The only child alive with ASA 
too had initial physical and mental development prob-
lems but is now catching up; however, the child has 
significantly delayed mental milestones and persis-
tently abnormal findings on LFTs. One child with ASA 
who was diagnosed early in life and was developing 
normally both physically and mentally, but died due to 
severe dengue infection associated with severe hyper-
ammonemia (ammonia levels > 3000 µmol/L), which 
could not be corrected despite dialysis. The child with 
ARGD has severe developmental delay with spastic 
diplegia and gets episodic hyperammonemia. He also 
has severe seizure episodes and mental retardation. He 
is awaiting a liver transplant.
Two children with citrullinemia type I (patient # 3 and 
patient # 17), 1 child with OTCD (patient # 30), and 
1 child with ARGD (patient # 33) have had multiple 
seizure episodes, usually generalized tonic and clonic, 
but these seizures were successfully treated with oral 
levetiracetam and phenobarbitone. All of them have 
abnormal findings on EEG. Seizures are common 
during acute encephalopathy and may be exacer-
bated by metabolic stressors such as fever or infec-
tion.17 EEG monitoring is recommended in the early 
course of treatment and during follow-up in acute 
cases. Seizure activity is thought to be related to hyper-
ammonemic crises or structural damage and subclin-
ical electrographic seizures.18 Valproate may interfere 
with the urea cycle and precipitate metabolic crises.18 
EEG is performed more often than MRI in our 
cohort of patients who are surviving with UCD, and 
we have found abnormal findings on EEG in 50% of 
the patients. Gropman et al2 (number of patients, n = 
26) found the incidence of cerebral palsy to be 46%, 
whereas in our cohort, it was 40% (4 of 10 alive 
patients) (Table 5). We found no patient with blindness 
but there is higher incidence of epilepsy in our cohort. 
Table 5. Neurologic Outcome
Disorder
Gropman et 
al2 (n = 26)
This Study (n = 10)
Normal — 20%







In males with late-onset OTCD, resulting from vari-
ants that permit partial enzyme functioning, cognitive 
outcome is better than in neonatal-onset presenters.2 In 
our cohort of 3 patients with OTCD, all were rather 
late presenters and presumed to have milder variants, 
especially the male patients. It is possible that in the 
Indian scenario, where there is no NBS and where the 
awareness of inborn errors of metabolism is at a very 
basal level, such neonatal severe forms are not detected, 
or even if detected, no attempt to treat is made. The 
common notion among general practitioners and even 
among pediatricians is that metabolic disorders cannot 
and should not be treated.
Prenatal diagnosis was performed for 1 couple whose 
3 children died of hyperammonemia. The couple was 
identified to be heterozygous carriers for c.991C>T 
mutation in exon 4 of NAGS gene.
One old retrospective study involving 88 patients has 
shown that of all the patients, 56% were symptomatic 
within 4 days of age and 67% within the first week. 
Thus, prevention of irreversible damage with the help 
of NBS using blood obtained at 3 to 4 days of life is 
questionable.19 Nowadays, the outcomes appear much 
better.
Conclusions
In India, owing to the absence of NBS, UCDs are 
detected only after development of symptoms, resulting 
in a high rate of morbidity and mortality (20 of 34). 
Citrullinemia is the commonest UCD (23 of 34), with 
the common mutation p.G390R found in 52.2% of 
patients. Early and aggressive treatment has resulted in 
good outcome in at least 2 patients and 4 children were 
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mildly affected. Unfortunately, 50% of the survivors 
have epilepsy, 40% have cerebral palsy, and 40% have 
complex neurobehavioral problems. We did not observe 
blindness in any of our patients.
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